NCT00871923View on ClinicalTrials.gov

Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

March 26, 2009

Primary Completion Date

December 4, 2019

Study Completion Date

December 4, 2019

Conditions
Non-small Cell Lung CancerBrain Cancer
Interventions
DRUG

Tarceva (Erlotinib hydrochloride)

150 mg by mouth every day beginning Day 1.

RADIATION

Radiation Therapy

Whole Brain Radiation Therapy (WBRT) for total dose of 3500cGy in 14 daily fractions beginning after Day 6.

Trial Locations (2)

77030

University of Texas MD Anderson Cancer Center, Houston

85721

University of Arizona, Tucson

Sponsors

Collaborators (1)

OSI Pharmaceuticals
All Listed Sponsors
collaborator

OSI Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00871923 - Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter